Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Dec. 31, 2019 | Feb. 13, 2020 | |
Document And Entity Information | ||
Entity Registrant Name | Luckwel Pharmaceuticals Inc. | |
Entity Central Index Key | 0001567098 | |
Document Type | 10-Q | |
Document Period End Date | Dec. 31, 2019 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --03-31 | |
Entity's Reporting Status Current | Yes | |
Entity Interactive Data Current | No | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business Flag | true | |
Entity Emerging Growth Company | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | true | |
Entity Common Stock, Shares Outstanding | 143,376,000 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2020 |
Condensed Balance Sheets
Condensed Balance Sheets - USD ($) | Dec. 31, 2019 | Mar. 31, 2019 |
Current Assets | ||
Cash | $ 33,916 | $ 25,754 |
Prepaid expense and other current assets | 13,133 | 1,516 |
Total Assets | 47,049 | 27,270 |
Current Liabilities: | ||
Accrued liabilities | 155,944 | 67,843 |
Due to officer | 1,068,874 | 751,250 |
Total Liabilities | 1,224,818 | 819,093 |
Stockholders' Deficit: | ||
Common stock, $0.01 par value; 200,000,000 shares authorized; 143,376,000 shares issued and outstanding as of December 31, 2019 and March 31, 2019, respectively | 1,433,760 | 1,433,760 |
Additional paid in capital | 465,748 | 465,748 |
Accumulated other comprehensive income | 10 | 10 |
Accumulated deficit | (3,077,287) | (2,691,341) |
Total stockholders' deficit | (1,177,769) | (791,823) |
Total Liabilities and Stockholders' Deficit | $ 47,049 | $ 27,270 |
Condensed Balance Sheets (Paren
Condensed Balance Sheets (Parenthetical) - $ / shares | Dec. 31, 2019 | Mar. 31, 2019 | Dec. 31, 2018 |
Statement of Financial Position [Abstract] | |||
Common stock, par value | $ 0.01 | $ 0.01 | |
Common stock, shares authorized | 200,000,000 | 200,000,000 | |
Common stock, shares issued | 143,376,000 | 143,376,000 | 143,376,000 |
Common stock, shares outstanding | 143,376,000 | 143,376,000 | 143,376,000 |
Condensed Statements of Operati
Condensed Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Statement [Abstract] | ||||
General and administrative expenses | $ (134,045) | $ (262,811) | $ (385,947) | $ (642,267) |
Other income (expense) | 1 | 1 | 5 | |
Net Loss | $ (134,045) | $ (262,810) | $ (385,946) | $ (642,262) |
Net loss per share - basic and diluted | $ (0.001) | $ (0.002) | $ (0.003) | $ (0.005) |
Weighted average common shares - basic and diluted | 143,376,000 | 143,376,000 | 143,376,000 | 128,376,000 |
Condensed Statements of Changes
Condensed Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($) | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income [Member] | Accumulated Deficit [Member] | Total |
Balance at Mar. 31, 2018 | $ 183,760 | $ 1,715,748 | $ 10 | $ (2,028,815) | $ (129,297) |
Balance, shares at Mar. 31, 2018 | 18,376,000 | ||||
Common stock issued for service | $ 1,250,000 | (1,250,000) | |||
Common stock issued for service, shares | 125,000,000 | ||||
Capital distribution | (40,000) | (40,000) | |||
Net loss | (642,262) | (642,262) | |||
Balance at Dec. 31, 2018 | $ 1,433,760 | 465,748 | 10 | (2,711,077) | (811,559) |
Balance, shares at Dec. 31, 2018 | 143,376,000 | ||||
Balance at Sep. 30, 2018 | $ 1,433,760 | 465,748 | 10 | (2,448,267) | (548,749) |
Balance, shares at Sep. 30, 2018 | 143,376,000 | ||||
Net loss | (262,810) | (262,810) | |||
Balance at Dec. 31, 2018 | $ 1,433,760 | 465,748 | 10 | (2,711,077) | (811,559) |
Balance, shares at Dec. 31, 2018 | 143,376,000 | ||||
Balance at Mar. 31, 2019 | $ 1,433,760 | 465,748 | 10 | (2,691,341) | (791,823) |
Balance, shares at Mar. 31, 2019 | 143,376,000 | ||||
Net loss | (385,946) | (385,946) | |||
Balance at Dec. 31, 2019 | $ 1,433,760 | 465,748 | 10 | (3,077,287) | (1,177,769) |
Balance, shares at Dec. 31, 2019 | 143,376,000 | ||||
Balance at Sep. 30, 2019 | $ 1,433,760 | 465,748 | 10 | (2,943,242) | (1,043,724) |
Balance, shares at Sep. 30, 2019 | 143,376,000 | ||||
Net loss | (134,045) | (134,045) | |||
Balance at Dec. 31, 2019 | $ 1,433,760 | $ 465,748 | $ 10 | $ (3,077,287) | $ (1,177,769) |
Balance, shares at Dec. 31, 2019 | 143,376,000 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Dec. 31, 2019 | Dec. 31, 2018 | |
Cash Flows from Operating Activities | ||
Net loss | $ (385,946) | $ (642,262) |
Adjustment to reconcile net loss to net cash used in operating activities: | ||
Prepaid expense and other current assets | (11,617) | (569) |
Expenses paid by officer | 59,024 | 281,019 |
Other payable and accrued liabilities | 88,101 | 21,343 |
Net cash flow used in operating activities | (250,438) | (340,469) |
Cash Flows from Financing Activities | ||
Capital distribution | (40,000) | |
Proceeds from officer loans | 258,600 | 404,883 |
Net cash flow provided by financing activities | 258,600 | 364,883 |
Net increase in cash | 8,162 | 24,414 |
Cash, beginning of period | 25,754 | 18,503 |
Cash, End of Period | 33,916 | 42,917 |
Supplemental disclosures of cash flow information: | ||
Cash paid for interest expense | ||
Cash paid for income taxes | ||
Noncash financing activities: | ||
Expenses paid by officer included as loan to officer | $ 59,024 | $ 281,019 |
Organization and Description of
Organization and Description of Business | 9 Months Ended |
Dec. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business | Note 1 – Organization and Description of Business Luckwel Pharmaceuticals Inc. (“Luckwel” or the “Company”) plans to acquire, develop, manufacture and market pharmaceutical medication. Luckycom Limited, a wholly-owned subsidiary of the Company, was incorporated in Hong Kong as Goldsans Capital (Hong Kong) Limited (“Goldsans”) on November 8, 2011. Goldsans name was changed to Wudor Capital Hong Kong Limited on May 22, 2012 and subsequently to Luckycom Limited on June 28, 2013. On April 11, 2018, Luckwel filed a Certificate of Amendment to the Articles of Incorporation to change its name from Luckycom Pharmaceuticals Inc. to Luckwel and to increase the number of its authorized shares of common stock to 200,000,000 with an effective date of April 13, 2018. The Company then amended and restated its by-laws to reflect the new corporate name. The Company’s corporate office is located in Waltham, Massachusetts and is incorporated in the State of Nevada. As used in this Quarterly Report on Form 10-Q (“Quarterly Report”), unless otherwise indicated, all references herein to “Luckwel,” the “Company,” “we” or “us” refer to Luckwel Pharmaceuticals Inc. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Dec. 31, 2019 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Note 2 - Summary of Significant Accounting Policies Preparation of Interim Financial Statements The accompanying condensed financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information and the Securities and Exchange Commission instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended December 31, 2019 are not necessarily indicative of the results that can be expected for the full year. The condensed financial statements contained herein should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019 filed with the SEC on July 2, 2019. These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. This assumption is presently uncertain and contingent upon the Company’s ability to raise additional working capital. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in US dollars (“USD”). Cash Cash includes all cash in bank with no restrictions. The Company had $33,916 and $25,754 of cash as of December 31, 2019 and March 31, 2019, respectively. Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, The Company’s financial instruments consist of cash, accrued liabilities and due to officer. The carrying amount of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three and nine months ended December 31, 2019 and December 31, 2018, respectively. Income Taxes During the three and nine months ended December 31, 2019 and 2018, there was no provision for income taxes as the Company incurred losses during both periods. Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. Uncertain Tax Positions The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized and recorded as necessary in the provision for income taxes. Tax years from 2013 forward remain open to examination by the U.S. federal tax authority due to the carryover of net operating losses or tax credits. According to Hong Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed at less than the proper amount. The statute of limitation is extended to 10 years if the underpayment of taxes is due to fraud or willful evasion. There were no uncertain tax positions as of December 31, 2019 and March 31, 2019. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basic and Diluted Net Loss Per Share Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted loss per share is calculated by dividing the Company’s net loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There were no potentially dilutive debt or equity outstanding as of December 31, 2019 and March 31, 2019, respectively. Recent Accounting Pronouncements The Company does not believe any recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the financial position, statements of operations and cash flows. |
Going Concern
Going Concern | 9 Months Ended |
Dec. 31, 2019 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Going Concern | Note 3 – Going Concern The Company does not have any sources of revenues and needs additional cash resources to maintain its operations. The Company has $33,916 in cash and a stockholders’ deficit of $1,177,769, has incurred losses since inception of $3,077,287, and has not yet received any revenue from sales of products or services. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital or obtain necessary debt financing. The Company is presently dependent on its Chief Executive Officer, Mr. Kingrich Lee to either provide the Company funding for its daily operation and expenses, including professional fees and fees charged by regulators, although he is under no obligation to do so, or to spearhead financing efforts with third parties. The Company currently does not have any arrangements in place to complete any financings and there is no assurance that it will be successful in completing any such financings on terms that will be acceptable. The Company’s priority, should it receive such additional funds, is to pay its legal, accounting and its filing obligations under United States federal securities laws, as well as to pay its other accounts payable generated in the ordinary course of business. The financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses and further losses are anticipated as a result of the development of business which raises substantial doubt about its ability to continue as a going concern within the next twelve months from the issuance date of the financial statements. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining financing necessary to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management intends to finance operating costs over the next twelve months with existing cash on hand and loans from directors and/or private placement of its common stock. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Dec. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Note 4 – Related Party Transactions The Company’s sole officer and director, and a shareholder, Mr. Kingrich Lee, loaned an aggregate of $258,600 in cash and made payments aggregating $59,024 on behalf of the Company during the nine months ended December 31, 2019. During the comparable period of 2018, he loaned an aggregate of $404,883 in cash and made aggregate payments of $281,019 on behalf of the Company. Accordingly, Mr. Kingrich Lee is owed an aggregate amount of $1,068,874 and $751,250 as of December 31, 2019 and March 31, 2019, respectively, from the Company. The amounts are unsecured, non-interest bearing and are due on demand. On May 3, 2018, the Company entered into an Intellectual Property Sale and Purchase Agreement (the “Agreement”) with Luckwel Asia Limited (the “Seller”, formerly known as Essential Choice Ventures Ltd), an entity under common control of Mr. Kingrich Lee to purchase from the Seller the intellectual property rights to five drugs, comprising three generic medicines used to treat hypertension and high cholesterol and two advanced drug candidates - KL008 for treatment of hypertension and KL009 for treatment of high cholesterol in various stages of being developed and manufactured (the “Transaction”). Pursuant to the terms of the Agreement, the Company agreed to pay the Seller on closing (i) $40,000 and (ii) issue an aggregate 125,000,000 restricted shares of its common stock, par value $0.01. The Transaction closed on May 3, 2018. The Company recorded the carrying value of the intellectual property as nil in the Seller’s record, $40,000 as capital distribution to the Seller and recorded the par value of the common stock as additional paid-in capital, which was due to the Transaction being regarded as an equity transaction because both parties were under common control. On November 1, 2017, the Company entered into an employment agreement with Mr. Kingrich Lee. The agreement is for one year, renewable for successive one-year terms if not terminated, and provides an annual compensation of $180,000, and other benefits, including housing and education allowances. On November 1, 2019, the Company renewed the employment agreement with Mr. Kingrich Lee for another one-year term. As of December 31, 2019, Mr. Kingrich Lee was owed $90,000 pursuant to his employment agreement, which is recorded in accrued expenses. |
Capital Stock
Capital Stock | 9 Months Ended |
Dec. 31, 2019 | |
Equity [Abstract] | |
Capital Stock | Note 5 – Capital Stock As of December 31, 2019 and 2018, the Company had 143,376,000 shares of common stock issued and outstanding. During the nine months ended December 31, 2018, the Company issued an aggregate of 125,000,000 restricted shares of its common stock to Luckwel Asia Limited. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Dec. 31, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Events | Note 6 – Subsequent Events On January 27, 2020, the Company received a loan of $27,000 from its’ sole officer and director, and a shareholder, Mr. Kingrich Lee. The loan is non-interest bearing and due on demand. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Dec. 31, 2019 | |
Accounting Policies [Abstract] | |
Preparation of Interim Financial Statements | Preparation of Interim Financial Statements The accompanying condensed financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial information and the Securities and Exchange Commission instructions to Form 10-Q. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Operating results for the interim period ended December 31, 2019 are not necessarily indicative of the results that can be expected for the full year. The condensed financial statements contained herein should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended March 31, 2019 filed with the SEC on July 2, 2019. These condensed financial statements have been prepared on the assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. This assumption is presently uncertain and contingent upon the Company’s ability to raise additional working capital. The financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. |
Basis of Presentation | Basis of Presentation The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and are presented in US dollars (“USD”). |
Cash | Cash Cash includes all cash in bank with no restrictions. The Company had $33,916 and $25,754 of cash as of December 31, 2019 and March 31, 2019, respectively. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurement, The Company’s financial instruments consist of cash, accrued liabilities and due to officer. The carrying amount of these financial instruments approximate fair value due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. There were no financial instruments classified as Level 3 in the fair value hierarchy during the three and nine months ended December 31, 2019 and December 31, 2018, respectively. |
Income Taxes | Income Taxes During the three and nine months ended December 31, 2019 and 2018, there was no provision for income taxes as the Company incurred losses during both periods. Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. |
Uncertain Tax Positions | Uncertain Tax Positions The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. Interest and penalties related to uncertain tax positions are recognized and recorded as necessary in the provision for income taxes. Tax years from 2013 forward remain open to examination by the U.S. federal tax authority due to the carryover of net operating losses or tax credits. According to Hong Kong Inland Revenue Department, the statute of limitation is six years if any company chargeable with tax has not been assessed at less than the proper amount. The statute of limitation is extended to 10 years if the underpayment of taxes is due to fraud or willful evasion. There were no uncertain tax positions as of December 31, 2019 and March 31, 2019. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Basic and Diluted Net Loss Per Share | Basic and Diluted Net Loss Per Share Basic loss per share is calculated by dividing the Company’s net loss applicable to common shareholders by the weighted average number of common shares during the period. Diluted loss per share is calculated by dividing the Company’s net loss available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted for any potentially dilutive debt or equity. There were no potentially dilutive debt or equity outstanding as of December 31, 2019 and March 31, 2019, respectively. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements The Company does not believe any recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the financial position, statements of operations and cash flows. |
Organization and Description _2
Organization and Description of Business (Details Narrative) - shares | Dec. 31, 2019 | Mar. 31, 2019 | Apr. 11, 2018 |
Common stock, shares authorized | 200,000,000 | 200,000,000 | |
Effective Date April 13, 2018 [Member] | |||
Common stock, shares authorized | 200,000,000 |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2019 | Dec. 31, 2018 | Mar. 31, 2019 | |
Accounting Policies [Abstract] | |||||
Cash | $ 33,916 | $ 33,916 | $ 25,754 | ||
Financial instruments, level 3 fair value hierarchy | |||||
Provision for income taxes | |||||
Minimum measure tax benefit likelihood percentage | 50.00% | 50.00% | |||
Uncertain tax positions | |||||
Potentially dilutive shares |
Going Concern (Details Narrativ
Going Concern (Details Narrative) - USD ($) | Dec. 31, 2019 | Sep. 30, 2019 | Mar. 31, 2019 | Dec. 31, 2018 | Sep. 30, 2018 | Mar. 31, 2018 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||||||
Cash | $ 33,916 | $ 25,754 | ||||
Stockholders' deficit | (1,177,769) | $ (1,043,724) | (791,823) | $ (811,559) | $ (548,749) | $ (129,297) |
Accumulated deficit | $ (3,077,287) | $ (2,691,341) |
Related Party Transactions (Det
Related Party Transactions (Details Narrative) - USD ($) | May 03, 2018 | Nov. 01, 2017 | Dec. 31, 2019 | Dec. 31, 2018 | Mar. 31, 2019 |
Proceeds from officer and director loan | $ 258,600 | $ 404,883 | |||
Due to officer | 1,068,874 | $ 751,250 | |||
Capital distribution | $ 40,000 | 40,000 | |||
Common stock, par value | $ 0.01 | $ 0.01 | |||
Intellectual property carrying value | |||||
Restricted Stock [Member] | |||||
Number restricted shares of common stock, shares | 125,000,000 | ||||
Common stock, par value | $ 0.01 | ||||
Mr. Kingrich Lee [Member] | |||||
Proceeds from officer and director loan | $ 258,600 | 404,883 | |||
Payment to related party | 59,024 | $ 281,019 | |||
Due to officer | 1,068,874 | $ 751,250 | |||
Agreement renewable term | 1 year | ||||
Officers compensation and other benefits, housing and education allowances | $ 180,000 | ||||
Mr. Kingrich Lee [Member] | Employment Agreement [Member] | |||||
Accrued expenses related parties | $ 90,000 |
Capital Stock (Details Narrativ
Capital Stock (Details Narrative) - shares | May 03, 2018 | Dec. 31, 2018 | Dec. 31, 2019 | Mar. 31, 2019 |
Common stock, shares issued | 143,376,000 | 143,376,000 | 143,376,000 | |
Common stock, shares outstanding | 143,376,000 | 143,376,000 | 143,376,000 | |
Restricted Stock [Member] | ||||
Number of common stock shares issued | 125,000,000 | |||
Luckwel Asia Limited [Member] | Restricted Stock [Member] | ||||
Number of common stock shares issued | 125,000,000 |
Subsequent Events (Details Narr
Subsequent Events (Details Narrative) | Jan. 27, 2020USD ($) |
Subsequent Event [Member] | Mr. Kingrich Lee [Member] | |
Received loan amount from related party | $ 27,000 |